Tag: Phase 3 trial
-
Sparsentan Delivers Positive Phase 3 Results in Japanese IgA Nephropathy
Overview: sparsentan earns positive topline data in Japanese IgA nephropathy Renalys Pharmaceutical Co. announced encouraging topline results from a Phase 3 study evaluating sparsentan, a dual-acting agent, in Japanese patients with IgA nephropathy (IgAN). The trial focused on the safety and efficacy of sparsentan in a specific, well-defined cohort (N=35) and sought to determine whether…
-
Bezuclastinib PEAK Phase 3: A Potential New Standard for KIT Exon 17/18 GIST
Bezuclastinib Hits Positive PEAK Phase 3 Results in Advanced GIST Gastrointestinal stromal tumors (GIST) have long been driven by KIT mutations, with targeted therapies reshaping patient outcomes over the past two decades. The emergence of resistance, particularly in those with KIT Exon 17 and Exon 18 mutations, has remained a persistent challenge. Bezuclastinib’s latest PEAK…